Clinical Trial Update: A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine [Phase 2]

View source ↗

Summary

Long-term extension study (Phase 2) evaluating immunogenicity and safety of CMV vaccine mRNA-1647; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• mRNA-1647 (Cytomegalovirus vaccine (mRNA-1647))

Snippet

Sponsor: ModernaTX, Inc. | Conditions: Cytomegalovirus Infection | Phase 2 | Status: COMPLETED